Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52

References

• Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12(6):475–81.
   PubMed Web of Science ®Google Scholar
• Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719–24.
   PubMed Web of Science ®Google Scholar
• Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19(6):523–9.
   PubMed Web of Science ®Google Scholar
• Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010;1184:134–53.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227–32.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Arnett FC, Reichlin M. Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum. 1988;31(4):515–24.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39(9):1507–18.
   PubMed Web of Science ®Google Scholar
• Bernstein RM, Bunn CC, Hughes GR, Francoeur AM, Mathews MB. Cellular protein and RNA antigens in autoimmune disease. Mol Biol Med. 1984;2(2):105–20.
   PubMedGoogle Scholar
• Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992;35(4):449–56.
   PubMed Web of Science ®Google Scholar
• Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360–74.
   PubMedGoogle Scholar
• Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 2006;54(6):2004–9.
   PubMed Web of Science ®Google Scholar
• Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev. 2009;8(7):632–7.
   PubMed Web of Science ®Google Scholar
• Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006;176(10):6277–85.
   PubMed Web of Science ®Google Scholar
• Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997;109(1):32–40.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002; 46(4):626–36.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11(6): 475–82.
   PubMedGoogle Scholar
• Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26(10):1647–54.
   PubMed Web of Science ®Google Scholar
• Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613.
   PubMed Web of Science ®Google Scholar
• Reeves WH, Satoh M. McAuliffe. Autoantibody testing by non-FITC methods. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of clinical laboratory immunology. 6th ed. Washington, DC: American Society of Microbiology Press; 2002:933–50.
   Google Scholar
• Chan EK, Hamel JC, Buyon JP, Tan EM. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest. 1991;87(1):68–76.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993–2000.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S, et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol. 2005;23(5):609–15.
   PubMed Web of Science ®Google Scholar
• Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14(2):R97.
   PubMed Web of Science ®Google Scholar
• Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, Jara LJ, Saavedra MA, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013; 15(2):R48.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682–9.
   PubMed Web of Science ®Google Scholar
• Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest. 1981;68(3): 611–20.
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65(12):1635–8.
   PubMed Web of Science ®Google Scholar
• Hudson M, Pope J, Mahler M, Taibouet S, Steele R Baron M. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012;14(2):R50.
   PubMed Web of Science ®Google Scholar
• Libirua-Iturburu A, Selva-O’Callaghan A, Vincze M, Danko K, Venkovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012;91(4):206–11.
   PubMed Web of Science ®Google Scholar
• Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11(10):739–45.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang GC, Ma Li Zu N. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol. 2012;35(11):686–91.
   PubMed Web of Science ®Google Scholar
• Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine. 2004;83(1):35–42.
   PubMed Web of Science ®Google Scholar